Opportunity Information: Apply for PAR 11 155
Apply for PAR 11 155
- The National Institutes of Health in the environment health income security and social services sector is offering a public funding opportunity titled "Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.856 Microbiology and Infectious Diseases Research 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research 93.867 Vision Research.
- This funding opportunity was created on Mar 16, 2011 and posted on Mar 16, 2011.
- Applicants must submit their applications by Sep 14, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments City or township governments Small businesses For profit organizations other than small businesses Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Independent school districts Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Organizations) are not eligible to apply, but may be members of consortia headed by U.S. institutions. Foreign (non U.S.) components of U.S. Organizations are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) funding opportunity (PAR-11-155) is a National Institutes of Health (NIH) cooperative agreement program aimed at speeding the development of medical treatments for harmful chemical exposures. The focus is on therapeutics that could be used to protect or treat people affected by toxic chemicals released intentionally (for example, through terrorism) or unintentionally (such as industrial accidents during production, storage, or transport). The chemicals of concern span classic chemical warfare agents like sarin and VX, as well as widely encountered toxic industrial chemicals and pesticides, including cyanide, chlorine, parathion, and sodium fluoroacetate. In practical terms, the program is built around translating scientific ideas into products or clinically relevant interventions that could realistically be used in emergency or real-world exposure settings.
This FOA supports a broad translational research pipeline rather than only early discovery or only late-stage testing. Projects can start at basic research steps such as identifying and validating biological targets, discovering or characterizing candidate countermeasures, and generating proof-of-concept data. From there, supported work can extend through candidate optimization (such as improving potency, selectivity, stability, delivery, dosing, or safety), and into rigorous demonstrations of in vivo efficacy in appropriate animal models. When justified and feasible, the program can also support later development activities including preparation for an Investigational New Drug (IND) submission and even Phase 1 clinical trials. The intent is to encourage projects that can move forward in a disciplined way from concept to something that is measurably closer to a usable medical countermeasure.
Because this is a U01 cooperative agreement rather than a standard research grant, applicants should expect substantial NIH program involvement during the life of the award, typically in the form of collaborative oversight, coordination, and involvement in key decisions consistent with the cooperative agreement mechanism. A defining feature of the program is the requirement for clearly defined milestones that create discrete, objective go/no-go decision points. These milestones are meant to impose a progressive translational plan where continuing investment is tied to hitting measurable benchmarks, reducing the risk of open-ended work that does not converge on a viable therapeutic pathway.
The opportunity is categorized as discretionary funding and falls under the broad activity category of environment, health, income security, and social services. It is associated with multiple CFDA program areas, reflecting the cross-cutting biomedical nature of chemical countermeasure development: 93.113 (Environmental Health), 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), 93.853 (Neurosciences and Neurological Disorders), 93.856 (Microbiology and Infectious Diseases Research), 93.859 (Biomedical Research and Research Training), 93.865 (Child Health and Human Development Extramural Research), and 93.867 (Vision Research). This mix signals that chemical threats can affect multiple organ systems and that viable countermeasures may emerge from diverse scientific domains.
Eligibility is broad and includes many types of U.S.-based organizations: state and local governments (including counties, cities or townships, special districts, independent school districts, and certain housing authorities), public and state-controlled and private institutions of higher education, nonprofits (including both 501(c)(3) and certain non-501(c)(3) entities), and for-profit organizations (including small businesses and other for-profits). The FOA also explicitly includes faith-based and community-based organizations, regional organizations, and a number of institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and tribal governments or organizations in the categories listed. Foreign (non-U.S.) organizations are not eligible to apply as the lead applicant, but they may participate as part of a consortium led by a U.S. institution, and foreign components of U.S. organizations are allowed. The FOA does not require cost sharing or matching.
Key dates show this was posted and created on March 16, 2011, with an original closing date of September 15, 2012, a current closing date listed as September 14, 2012, and an archive date of October 15, 2012. The full announcement was made available through NIH at the link provided in the notice (http://grants.nih.gov/grants/guide/pa-files/PAR-11-155.html). For access or technical issues, the FOA directs applicants to contact the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
CounterACT Cooperative Research Projects (U01) (PAR-11-155) - FAQs
What is PAR-11-155 (CounterACT Cooperative Research Projects, U01)?
PAR-11-155 is a National Institutes of Health (NIH) funding opportunity under the Countermeasures Against Chemical Threats (CounterACT) program that uses the U01 cooperative agreement mechanism. It is intended to speed the development of medical treatments (therapeutics) for harmful chemical exposures, supporting work that translates scientific ideas into products or clinically relevant interventions that could be used in emergencies or real-world exposure settings.
What is the primary goal of the CounterACT U01 program?
The main goal is to accelerate the development of medical countermeasures that can protect or treat people exposed to toxic chemicals, whether the release is intentional (for example, terrorism) or unintentional (for example, industrial accidents during chemical production, storage, or transport).
What kinds of chemical threats are covered by this opportunity?
The FOA covers a range of chemicals, including classic chemical warfare agents (such as sarin and VX) and widely encountered toxic industrial chemicals and pesticides. Examples listed include cyanide, chlorine, parathion, and sodium fluoroacetate.
What types of projects does this FOA aim to support?
This FOA supports translational research aimed at developing therapeutics that could realistically be used in emergency or real-world chemical exposure scenarios. The emphasis is on moving from scientific concepts toward usable medical countermeasures through a structured, milestone-driven development plan.
Does this funding opportunity support only early-stage research or only late-stage development?
No. The FOA supports a broad translational research pipeline rather than being limited to only early discovery or only late-stage testing. Projects may start at earlier steps and extend into later development activities when justified and feasible.
What early-stage activities can be supported under this FOA?
Examples of early-stage activities described include identifying and validating biological targets, discovering or characterizing candidate countermeasures, and generating proof-of-concept data.
What optimization and preclinical development work can be supported?
The FOA notes support may extend through candidate optimization, such as improving potency, selectivity, stability, delivery, dosing, or safety, and through rigorous demonstrations of in vivo efficacy in appropriate animal models.
Can this FOA support IND-enabling work and clinical trials?
Yes, when justified and feasible. The FOA indicates support can include preparation for an Investigational New Drug (IND) submission and even Phase 1 clinical trials.
What does it mean that this award uses the U01 cooperative agreement mechanism?
Because this is a U01 cooperative agreement rather than a standard research grant, applicants should expect substantial NIH program involvement during the life of the award. The FOA describes this involvement as collaborative oversight, coordination, and participation in key decisions, consistent with the cooperative agreement mechanism.
What are milestones and go/no-go decision points, and are they required?
Yes, they are a defining feature of this program. The FOA requires clearly defined milestones that create discrete, objective go/no-go decision points. These milestones are intended to enforce a progressive translational plan where continued investment is tied to hitting measurable benchmarks.
Why does the FOA emphasize milestones?
The FOA explains that milestones reduce the risk of open-ended work that does not converge on a viable therapeutic pathway by linking continued support to measurable progress.
What is the funding type and activity category for this opportunity?
The opportunity is categorized as discretionary funding and is listed under the broad activity category of environment, health, income security, and social services.
Which CFDA program areas are associated with this FOA?
The FOA is associated with multiple CFDA areas: 93.113 (Environmental Health), 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), 93.853 (Neurosciences and Neurological Disorders), 93.856 (Microbiology and Infectious Diseases Research), 93.859 (Biomedical Research and Research Training), 93.865 (Child Health and Human Development Extramural Research), and 93.867 (Vision Research).
What does it mean that multiple CFDA areas are listed?
Based on the FOA description, the mix of CFDA areas reflects the cross-cutting biomedical nature of chemical countermeasure development, including the reality that chemical threats can affect multiple organ systems and that countermeasures may come from diverse scientific domains.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S.-based organizations, including state and local governments, public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), and for-profit organizations (including small businesses and other for-profits). The FOA also explicitly includes faith-based and community-based organizations, regional organizations, and various institution types (for example, HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and tribal governments or organizations in the listed categories).
Are foreign (non-U.S.) organizations eligible to apply as the lead applicant?
No. The FOA states that foreign (non-U.S.) organizations are not eligible to apply as the lead applicant.
Can foreign organizations participate in projects funded under this FOA?
Yes. While foreign organizations cannot be the lead applicant, the FOA states they may participate as part of a consortium led by a U.S. institution. The FOA also allows foreign components of U.S. organizations.
Is cost sharing or matching required?
No. The FOA states that cost sharing or matching is not required.
When was this funding opportunity posted and created?
The FOA indicates it was posted and created on March 16, 2011.
What were the closing and archive dates listed for this FOA?
The FOA lists an original closing date of September 15, 2012, a current closing date of September 14, 2012, and an archive date of October 15, 2012.
Where can applicants find the full NIH announcement for PAR-11-155?
The FOA states the full announcement is available through NIH at: http://grants.nih.gov/grants/guide/pa-files/PAR-11-155.html
Who should be contacted for access or technical issues related to the FOA?
For access or technical issues, the FOA directs applicants to contact the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Environment Health Income Security and Social Services
Next opportunity: Minority Fellowship Program
Previous opportunity: Migratory Bird Monitoring, Assessment and Conservation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 11 155
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 11 155) also looked into and applied for these:
| Funding Opportunity |
|---|
| Autism Centers of Excellence Centers (P50) Apply for RFA HD 12 195 Funding Number: RFA HD 12 195 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,500,000 |
| Autism Centers of Excellence Networks (R01) Apply for RFA HD 12 196 Funding Number: RFA HD 12 196 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 155", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.